Farukh Kitchlew | Dec 6, 2023 | 0
Apollo bags an impressive $226.5M in Series C
Apollo Therapeutics, a leading biopharmaceutical company, has recently secured $226.3\5 million in a Series C funding round. This significant financial boost is poised to accelerate the development of groundbreaking medicines, potentially revolutionizing the healthcare landscape. Patient Square Capital led the round, including M&G plc and two of the largest US public pension plans. The firm also saw existing investor Rock Springs Capital participate in the round.
The funding is a testament to Apollo Therapeutics’ commitment to advancing innovative medical solutions. The investment, provided by a consortium of esteemed backers, underscores the recognition of the company’s pioneering research and development efforts.